KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2025)

Historic EBT Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 0.67%.

  • Amneal Pharmaceuticals' EBT Margin fell 28600.0% to 0.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.34%, marking a year-over-year increase of 69300.0%. This contributed to the annual value of 1.97% for FY2024, which is 2900.0% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' EBT Margin stood at 0.67%, which was down 28600.0% from 7.14% recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year EBT Margin high stood at 7.14% for Q2 2025, and its period low was 41.61% during Q2 2022.
  • Moreover, its 5-year median value for EBT Margin was 0.39% (2021), whereas its average is 2.18%.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBT Margin tumbled by -481200bps in 2022, and later surged by 465600bps in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' EBT Margin (Quarter) stood at 3.04% in 2021, then soared by 59bps to 1.26% in 2022, then tumbled by -978bps to 13.53% in 2023, then soared by 84bps to 2.1% in 2024, then skyrocketed by 68bps to 0.67% in 2025.
  • Its last three reported values are 0.67% in Q3 2025, 7.14% for Q2 2025, and 5.39% during Q1 2025.